Memorial Sloan Kettering Studied Pancreatic Cancer Treatment
Researchers analyzed patient survival outcomes using magnetic resonance-guided adaptive radiotherapy.
Updated on Oct. 6, 2026 in Cancer
Researchers at Memorial Sloan Kettering Cancer Center have shared clinical results for a specialized radiation therapy used on 123 patients with localized pancreatic cancer. The study evaluated high-dose adaptive radiotherapy sessions delivered to patients who were not candidates for surgical resection.
Why it matters
Pancreatic tumors often shift position relative to healthy organs between treatment sessions, making precise targeting difficult. This radiotherapy approach uses daily imaging to adjust radiation delivery to a patient's specific anatomy in real time.
The study observed 76.8% local tumor control at two and three years among 123 patients. The median follow-up period for these participants exceeded two years.
The players
Memorial Sloan Kettering Cancer Center
This is a New York-based cancer treatment and research institution that conducts clinical trials to improve oncological care standards.
ASTRO
The American Society for Radiation Oncology is a professional organization that hosts annual conferences to share advancements in radiotherapy research.
Elekta
This medical technology company specializes in the development of precision radiation therapy equipment and software platforms.
The details
The treatment utilized the Elekta Unity MR-Linac to administer high-dose radiation over five sessions across two weeks. By performing daily online MR imaging, medical teams were able to recalibrate the radiation delivery to account for internal organ movement.
Timeline
Patients received treatments between May 2020 and December 2024.
Results were presented at the ASTRO 2026 conference on October 1, 2026.
The Big Picture
This study follows the clinical validation of the Elekta Unity MR-Linac technology platform for complex tumor targeting. The research highlights the evolution of adaptive radiotherapy as a standard for treating patients who cannot undergo surgical intervention.
This radiotherapy method provides a non-surgical alternative for patients with localized pancreatic cancer who may not be eligible for operations. The daily adjustments allow for higher-dose precision that may improve tumor control in challenging abdominal regions.
The takeaway
Adaptive radiotherapy represents a significant shift toward precision medicine by accounting for anatomical shifts in real time. Patients and their care teams should consult with oncology specialists to determine if such advanced imaging-guided therapies align with their specific treatment plans.
Further reading
Learn more about the latest developments in cancer treatment at the Cancer section.
Source note: This article includes information reported by Imaging Technology News.
